← stocks-llm New chat

HCAT vs OMCL

HCAT: Health Catalyst provides cloud-based data analytics and improvement services to healthcare systems, but faces significant headwinds from customer financial strain, platform migration challenges, and macroeconomic pressures on healthcare budgets. OMCL: Omnicell automates medication management across healthcare settings through storage, dispensing, and intelligence solutions to enable safer, more efficient pharmacy operations.

Side-by-side fundamentals

MetricHCATOMCLEdge
Price as of 2026-07-27 close$2.15$41.49
Market cap as of 2026-07-29$157M$1.9B
P/E as of 2026-07-29n/a94.06
PEG as of 2026-07-29-0.002.94HCAT lower
Net margin as of 2026-07-29-87.7%+1.7%OMCL higher
Gross margin as of 2026-07-29+50.4%+43.5%HCAT higher
Operating margin as of 2026-07-29-81.7%+2.8%OMCL higher
ROE as of 2026-07-29-99.8%+1.6%OMCL higher
ROA as of 2026-07-29-50.1%+1.0%OMCL higher
Debt / equity as of 2026-07-291.110.13OMCL lower
Revenue growth (YoY) as of 2026-07-29-2.8%+7.9%OMCL higher
Revenue CAGR (3y) SEC XBRL+4.0%-2.9%HCAT higher
Beta as of 2026-07-291.540.96
1-year return as of 2026-07-27 close-44.6%+46.8%OMCL higher

Fundamentals: Finnhub, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-27.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.